Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.
Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.